Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies

Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies
复制标题

DOI:
10.1191/096120300674499064
复制
发表时间:
2000-01-01
期刊:
影响因子:
2.6
通讯作者:
Rönnblom, L
Rönnblom, L
中科院分区:
医学4区
文献类型:
--
作者:
Bengtsson, AA;Sturfelt, G;Rönnblom, L

文献摘要

被引文献

相似文献

目的是研究SLE患者血清干扰素-α(IFN-α)水平、内源性IFN-α诱导因子(SLE-IIF)活性、临床和免疫学疾病活动性以及血清抗逆转录病毒抗体水平之间的关系。在疾病活动的不同阶段(SLEDAI评分)采样的30名患者的系列血清中测量IFN-α的血清水平。通过其在正常外周血单核细胞培养物中诱导IFN-α产生的能力来测量SLE-IIF活性。在连续随访的患者中,血清IFN-α和SLE-IIF在发作时均显著升高。SLEDAI评分、抗dsDNA抗体和IL-10水平与血清IFN-α浓度呈正相关,补体成分C1 q、C3和白细胞与血清IFN-α浓度呈负相关。多器官受累程度与血清IFN-α水平相关。逆转录病毒肽结合抗体的浓度和IFN-α或SLE-IIF活性之间没有关系被发现。SLE患者的疾病活动性和IFN-α血清水平之间的密切关系表明,I型IFN系统的激活可能在疾病过程中的重要性。
The objective was to investigate the relation between serum levels of interferon-alpha (IFN-alpha), the activity of an endogenous IFN-alpha inducing factor (SLE-IIF), clinical and immunological disease activity as well as serum levels of antiretroviral antibodies in SLE. Serum levels of IFN-alpha were measured in serial sera from 30 patients sampled at different stages of disease activity (SLEDAI score). The SLE-IIF activity was measured by its ability to induce IFN-alpha production in cultures of normal peripheral blood mononuclear cells. Both serum IFN-alpha and SLE-IIF increased markedly at flare in serially followed patients. The SLEDAI score, levels of anti-dsDNA antibodies and IL-10 correlated positively, and complement components Clq, C3 and leukocytes correlated inversely with serum concentrations of IFN-alpha. The extent of multiple organ involvement correlated with serum IFN-alpha. No relation between concentrations of retroviral peptide binding antibodies and IFN-alpha or SLE-IIF activity was found. The close relationship between disease activity in SLE patients and IFN-alpha serum levels suggests that activation of the type I IFN system might be of importance in the disease process.